Comparison between bacteremia caused by carbapenem resistant Acinetobacter baumannii and Acinetobacter nosocomialis

Table 3 Antimicrobials used for the patients with carbapenem resistant Acinetobacter baumannii and Acinetobacter nosocomialis bacteremia*

Main agents used	No. of patients	APACHE II score	No. (%) of patients
		Median (interquartile range)	Appropriate antimicrobial therapy	14–day mortality
Anti-pseudomonal penicillins^a
CRAB	12	31.5(22.8–39.0)	2(16.7)	6(50.0)
CRAN	8	24(19.0–33.0)	7(87.5)	2(25.0)
Anti-pseudomonal cephalosporins^b
CRAB	14	26(22.8–34.0)	2(14.3)	4(28.6)
CRAN	10	26(19.3–30.0)	7(70.0)	1(10.0)
Anti-pseudomonal fluoroquinolones^c
CRAB	5	30(21.0–36.0)	1(20.0)	2(40.0)
CRAN	2	37.5(37.0–38.0)	2(100.0)	0(0)
Anti-pseudomonal carbapenems^d
CRAB	17	32(24.0–38.5)	0(0)	7(41.2)
CRAN	14	30.5(23.0–33.3)	0(0)	2(14.3)
Ampicillin/sulbactam or sulbactam
CRAB	11	17(15.0–33.0)	4(36.4)	5(45.5)
CRAN	8	24(18.0–27.5)	3(37.5)	0(0)
Non-antipseudomonal β-lactamases^e
CRAB	6	17.5(15.3–25.3)	0(0)	1(16.7)
CRAN	9	18(15.5–24.0)	3(33.3)	1(11.1)
Miscellaneous
CRAB	6	25(17.8–32.0)	0(0)	2(33.3)
CRAN	13	27(16.0–35.5)	0(0)	3(23.1)

*Data are median value (interquartile range) for continuous variables and number of cases (%) for categorical variables. ^aIncluding piperacillin, piperacillin/tazobactam, and ticarcillin/clavulanate. ^bIncluding cefoperazone, ceftazidime, cefepime, and cefpirome. ^cIncluding ciprofloxacin and levofloxacin. ^dIncluding imipenem and meropenem. ^eIncluding penicillin, amoxicillin/clavulanate, cefazolin, cefuroxime, cefotaxime, cefmetazole, and flomoxef. APACHE II Acute Physiologic and Chronic Health Evaluation II, CRAB carbapenem resistant A. baumannii, CRAN carbapenem resistant A. nosocomialis.

ISSN: 1471-2334